Patients with PD-L1 positive tumor showed significantly higher TILs levels and the hazard ratio showed a larger benefit from atezolizumab/T-DM1 vs. placebo/T-DM1 in patients with TILs > 5% (HR 0.55, 95% CI 0.26–1.12) as compared to patients with lower TILs (HR 1.43, 95% CI 0.51–4.01). The gene discussed is CD274; the disease is neoplasm.